LRRK2 and Parkinson disease: This idea is strengthened by the fact that the administration of taxol, a MT stabilizing agent, or the expression of either WT parkin or WT LRRK2 in PD patient fibroblasts, provokes an increase in the polymerized MTs and a recovery of the cell morphology and behavior.